Opposing adrenergic actions of intravenous metformin on arterial pressure in female spontaneously hypertensive rats

Cardiovascular Research

Volumn 43, Issue 1, 1999, Pages 237-247

  Peuler, Jacob D ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Autonomic nervous system; Blood pressure; Diabetes; Experimental; Hypertension; Pharmacology; Regulatory systems; Vasoconstriction dilation

Indexed keywords

ADRENALIN; METFORMIN; NORADRENALIN;

ADRENALIN BLOOD LEVEL; ADRENERGIC ACTIVITY; ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GANGLION BLOCK; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; SPONTANEOUSLY HYPERTENSIVE RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CHLORISONDAMINE; FEMALE; GANGLIONIC BLOCKERS; HEART RATE; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENOUS; METFORMIN; NOREPINEPHRINE; PHENYLEPHRINE; PROPRANOLOL; RATS; RATS, INBRED SHR;

EID: 0032999474     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00051-6     Document Type: Article

References (37)

1. Montaguti U., Celin D., Ceredi C., Descovich G.C. Efficacy of the long-term administration of metformin in hyperlipidaemic patients. Res. Clin. Forum. 1:1979;95-103.
2. Haupt E., Knick B., Koschinsky T., Liebermeister H., Schneider J., Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabet Metab. 17:1991;224-231.
3. Landin K., Tengborn L., Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J. Int. Med. 229:1991;181-187.
4. Calle-Pascual A.L., Garcia-Honduvilla J., Martin-Alverez P.J., et al. Comparison between acarbose, metformin and insulin treatment in type-2 diabetic patients with secondary failure to sulphonylurea treatment. Diabet. Metab. 21:1995;256-260.
5. Giugliano D., De Rosa N., Di Maro G., et al. Metformin improves glucose lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 16:1993;1387-1390.
6. Giugliano D., Quatraro A., Consoli G., et al. Metformin for obese, insulin-treated diabetic patients. Improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol. 44:1993;107-112.
7. Mendoza S.G., Faieta A., Carrasco H., Hamer T., Glueck C.J. Metformin lowers blood pressure, insulin resistance, triglycerides and endogenous estradiol in hypertensive men [abstract]. Clin. Res. 42:1994;336A.
8. Fanghanel G., Sanchez-Reyes L., Trujillo C., Sotres D., Espinosa-Campos J. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care. 19:1996;1185-1189.
9. Chan J.C.N., Tomlinson B., Critchley J.A.J.H., Cockram C.S., Walden R.J. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care. 16:1993;1035-1038.
10. Snorgaard O., Kober L., Carlsen J. The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J Int Med. 242:1997;407-412.
11. Semplicini A., Del Prato S., Giusto M., et al. Short-term effects of metformin on insulin sensitivity and sodium homeostasis in essential hypertensives. J. Hypertens. 11:(suppl 5):1993;S276-S277.
12. Gudbjörnsdottir S., Friberg P., Elam M., Attvall S., Lönnroth P., Wallin B.G. The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. Blood Pressure. 3:1994;394-403.
13. Dorella M., Giusto M., Da Tos V., et al. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. J. Clin. Endocrinol. Metab. 81:1996;1568-1574.
14. Hermann L.S., Schersten B., Bitzen P., Kjellström T., Lindgarde F., Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double blind controlled study. Diabetes Care. 17:1994;1100-1109.
15. Robinson A.C., Burke J., Robinson S., Johnston D.G., Elkeles R.S. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care. 21:1998;701-705.
16. Sundaresan P., Lykos D., Daher A., Diamond T., Morris R., Howes L.G. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM. Diabetes Care. 20:1997;692-697.
17. Campbell I.W., Duncan C., Patton N.W., Broadhead T., Tucker G.T., Woods H.F. The effects of metformin on glycemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus. Diabet. Med. 4:1987;337-341.
18. Fontbonne A., Charles M.A., Juhan-Vague I., et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care. 19:1996;920-926.
19. Wright A.D., Cull C.A., Holman R.R., Turner R.C. UKPDS 28 - A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care. 21:1998;87-92.
20. Petersen J.S., DiBona G.F. Acute sympathoinhibitory actions of metformin in spontaneously hypertensive rats. Hypertension. 27:1996;619-625.
21. Petersen J.S., Liu W., Kapusta D.R., Varner K.J. Metformin inhibits ganglionic neurotransmission in renal nerves. Hypertension. 29:1997;1173-1177.
22. Muntzel M.S., Abe A., Petersen J.S. Effects of adrenergic, cholinergic and ganglionic blockade on acute depressor responses to metformin in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 281:1997;618-623.
23. Abdel-Rahman A.R. Inadequate blockade by hexamethonium of the baroreceptor heart rate response in anesthetized and conscious rats. Arch Int Pharmacodyn Ther. 297:1989;68-85.
24. Santajuliana D., Hornfeldt B.J., Osborn J.W. Use of ganglionic blockers to assess neurogenic pressor activity in conscious rats. J. Pharmacol. Toxicol. Meth. 35:1996;45-54.
25. Miller J.A., Peuler J.D. Rapid vasorelaxation by high levels of metformin [abstract]. FASEB J. 10:1996;A700.
26. Lee J.M., Peuler J.D. Acute vasorelaxant effects of metformin and attenuation by stimulation of sympathetic agonist release. Life Sci. 64:(4):1998;PL57-PL63.
27. 2+]. J. Hypertens. 15:1997;269-274.
28. Imai K., Higashidate S., Prados P.R., Santa T., Adachi-Akahane S., Nagao T. Relation between blood pressure and plasma catecholamine concentration after administration of calcium antagonists to rats. Biol. Pharm. Bull. 17:1994;907-910.
29. Peuler J.D. Adrenergic depressor and pressor actions of metformin in spontaneously hypertensive rats [abstract]. Am. J. Hypertens. 10:1997;107A.
30. McClintock M.K. Estrous synchrony and its mediation by airborne chemical communication (Rattus norvegicus). Hormones and Behavior. 10:1978;264-276.
31. McClintock M.K. Estrous synchrony: Modulation of ovarian cycle length by female pheromones. Physiol. Behav. 32:1984;701-705.
32. Peuler J.D., Schelper R.L. Partial protection from salt-induced stroke and mortality by high oral calcium in hypertensive rats. Stroke. 23:1992;532-538.
33. Peuler J.D., Johnson B.A.B., Phare S.M., Sowers J.R. Sex specific effects of an insulin secretagogue in stroke-prone hypertensive rats. Hypertension. 22:1993;214-220.
34. Peuler J.D., Edwards G.L., Schmid P.G., Johnson A.K. Area postrema and differential reflex actions of vasopressin and phenylephrine in rats. Am. J. Physiol. 258:1990;H1255-H1259.
35. Peuler J.D., Johnson G.A. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine, and dopamine. Life Sci. 21:1977;625-636.
36. Verma S., Bhanot S., McNeill J.H. Decreased vascular reactivity in metformin-treated fructose-hypertensive rats. Metabolism. 45:1996;1053-1055.
37. Verma S., McNeill J.H. Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts. Am J Physiol. 266:1994;H714-H719.